Corbus Pharmaceuticals I... (CRBP)
8.09
-0.26 (-3.11%)
At close: Apr 25, 2025, 3:59 PM
8.48
4.89%
After-hours: Apr 25, 2025, 05:56 PM EDT
-3.11% (1D)
| Bid | 7.86 |
| Market Cap | 98.9M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -40.21M |
| EPS (ttm) | -3.68 |
| PE Ratio (ttm) | -2.2 |
| Forward PE | -1.52 |
| Analyst | Buy |
| Ask | 8.73 |
| Volume | 207,064 |
| Avg. Volume (20D) | 236,404 |
| Open | 8.72 |
| Previous Close | 8.35 |
| Day's Range | 7.92 - 8.72 |
| 52-Week Range | 4.64 - 61.90 |
| Beta | 3.13 |
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the act...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 27, 2014
Employees 28
Stock Exchange NASDAQ
Ticker Symbol CRBP
Website https://www.corbuspharma.com
Analyst Forecast
According to 9 analyst ratings, the average rating for CRBP stock is "Buy." The 12-month stock price forecast is $52, which is an increase of 543.17% from the latest price.
Stock Forecasts7 months ago
-62.26%
Corbus Pharmaceuticals Holdings shares are trading...
Unlock content with
Pro Subscription
10 months ago
+14.68%
Corbus Pharmaceuticals Holdings shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $77 to $82.
